Body mass index (BMI) has long been a common tool for estimating a person's relative weight status based on a simple height to weight ratio. It's easy to calculate, widely accessible and often used ...

Stocks are struggling at the start of trade as lingering trade worries stick to this market, though investors managed to shake that off on Monday. That setup could work again for Tuesday. The S&P 500 ...

Weight-loss drugs among breakthrough trials offering ‘hope’ for dementia prevention - One clinical trial is assessing whether ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

An oral drug that improves vision in diabetic macular edema (DME) would be a game changer because it would be more ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The MUSC Weight Management Center (WMC) is casting a lifeline to plus-sized individuals at wit's end with their apple cider ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...